-

12:46:55 AM

Latest ABVC Stock Market News

ABVC - ABVC BioPharma Inc

09/13/21 8:30 AM

Nasdaq, OTC : ABVC

clinical trial

ABVC BioPharma Completes Site Selection for ABV-1505 ADHD Phase II Part 2 Clinical Study

via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced

RHEA-AI

neutral

09/01/21 8:30 AM

Nasdaq, OTC : ABVC

ABVC BioPharma Announces New PCT Filings for MDD and ADHD Treatments

via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it has filed new PCT (Patent Cooperation Treaty)

RHEA-AI

neutral

08/30/21 8:30 AM

Nasdaq, OTC : ABVC

ABVC BioPharma Report Updated by Zacks/SCR

via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Zacks Small Cap Research has issued an update

RHEA-AI

neutral

08/26/21 8:30 AM

Nasdaq, OTC : ABVC

ABVC BioPharma Provides Vitargus® Update

via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today provided an update regarding recent developments in connection

RHEA-AI

neutral

08/12/21 8:27 AM

Nasdaq, OTC : ABVC

ABVC BioPharma Reports Second Quarter 2021 Results

ABVC Biopharma, Inc., a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous system (CNS), and ophthalmology,

RHEA-AI

neutral

08/06/21 8:30 AM

Nasdaq : ABVC

offering

WallachBeth Capital Announces the Completion of an Underwritten Public Offering of 1,100,000 Units for ABVC BioPharma, Inc.

WallachBeth Capital, a leading provider of capital markets and institutional execution services, announced the completion of an underwritten public offering of 1,100,000 units for ABVC BioPharma, Inc. (NASDAQ: Common stock – ABVC) at an offering price

RHEA-AI

neutral

08/03/21 8:30 AM

Nasdaq, OTC : ABVC

ABVC BioPharma, Inc. Announces Pricing of $6.875 Million Firm Commitment Offering

ABVC BioPharma, Inc. (ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous system (CNS), and ophthalmology, today announced the pricing of its firm commitment

RHEA-AI

neutral